-
Sequenom recently released data suggesting its real-world performance tracked with trial results, based on physician feedback.
WSJ: New Questions on Cutting-Edge Prenatal Tests
-
"It's not the same type quality control as a controlled trial, " Sequenom's Dr. Bombard said, though he expects doctors to proactively report unusual results.
WSJ: New Questions on Cutting-Edge Prenatal Tests
-
Earlier this month, Sequenom made a hostile bid for Exact Sciences.
FORBES: Magazine Article
-
"I'm doing everything I can do to promote the message" that positive results should be confirmed with invasive testing, said Allan Bombard, chief medical officer at Sequenom.
WSJ: New Questions on Cutting-Edge Prenatal Tests
-
For the September quarter, sales were up 17% at Sequenom.
FORBES: Magazine Article
-
"All patients want to hear that you don't need to have something invasive, " said Laura Limone, genetic-counseling supervisor at the perinatal group and a member of Sequenom's speakers bureau.
WSJ: New Questions on Cutting-Edge Prenatal Tests
-
Sequenom is developing a high-speed "bacterial fingerprinting" technique based on mass spectrometry that can be used to rapidly identify the DNA of subtly different strains of bacteria or viruses.
FORBES: Biotechs See Dollar Signs In War
-
The tool is being used by 16 companies and research institutes, including Sequenom, a biotech firm in San Diego, California, and by the Indian government, to track drugs to treat a new strain of malaria.
FORBES: Magazine Article
-
Sequenom has some deeply committed investors.
FORBES: Smart Trade In The Genes
-
"Given the economic climate, everyone is trying to get in line at the trough, " says Charles Cantor , a bioterrorism expert and chief scientific officer at San Diego biotech firm Sequenom (nasdaq: SQNM - news - people ).
FORBES: Biotechs See Dollar Signs In War
-
The tool is being used by 16 companies and research institutes, including Sequenom, (nasdaq: SQNMD - news - people ) a biotech firm in San Diego, California, and by the Indian government, to track drugs to treat a new strain of malaria.
FORBES: Consultants From Chennai